• Home
  • Science
    • ImmunoBody®
    • Moditope®
    • Glymab®
    • Publications
  • Pipeline
  • News
  • Investors
    • Share Info
    • Financial Info
    • Documents & Presentations
    • Corporate Governance
  • Contact Us
    • Find a trial
    • Become an Investigator

Form F-4 (October 2026)

by admin | Oct 9, 2026 | SEC Filings

Atlantic crossing transforms outlook

by chantal | Oct 6, 2026 | Trinity Delta Reports

Notice of General Meeting October 2026

by admin | Oct 2, 2026 | Annual General Meeting 2026

Form of Proxy

by admin | Oct 2, 2026 | Annual General Meeting 2026

Comparison of Articles of Association

by admin | Oct 2, 2026 | Annual General Meeting 2026

Proposed Amended Articles of Association

by admin | Oct 2, 2026 | Annual General Meeting 2026

« Older Entries

Recent Posts

  • Result of General Meeting
  • Form F-4 (October 2026)
  • Preliminary Results for the year ended 30 April 2026
  • Atlantic crossing transforms outlook
  • Notice of General Meeting October 2026

Recent Comments

No comments to show.

Scancell is focused on developing novel immunotherapies for the treatment of cancer and was founded in 1996 based on research led by Professor Lindy Durrant at the University of Nottingham in the UK.

  • Follow
  • Follow

Science
Our Pipeline
News
Contact Us
Find a Trial
Become an Investigator

ACTIVE IMMUNOTHERAPY

ImmunoBody®
Moditope®

ANTIBODIES

GlyMab®
AvidiMab®

Investors
Company Profile
Advisors
Corporate Governance
Documents & Presentations
Share Information
Financial Information

Copyright © 2026 Scancell | Website Designed & Developed by Identity Creative | Privacy & Cookie Policy